Zeus, the world's leading polymer extrusion and catheter design manufacturer, announced the appointment of Padraic "Paddy" O'Brien as chief executive officer, effective April 1, 2024.
Company officials said O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
O'Brien is currently Worldwide President of BD Peripheral Intervention at Becton, Dickinson, and Company (NYSE: BDX), a medical technology company focused on advancing clinical therapy for patients and clinical process for health care providers.
Before that, he held various leadership positions within BD, where he developed an extensive and consistent track record of delivering durable, sustainable growth while creating a winning culture.
From 2001-2016, he held a series of ascending management positions within Bard until BD acquired the company in December 2017.
O'Brien holds a bachelor’s degree in combined sciences (Biology and Chemistry) from Santa Clara University.
Ethan Waxman, partner within EQT Private Equity's Advisory Team, said: "We undertook an extensive search to find Zeus' next CEO, and Paddy's deep domain knowledge and experience make him perfectly suited to lead the company through this next phase of growth."
Waxman added, "We look forward to partnering with Paddy as we make significant investments in increased capacity, process improvement, and product innovation."
Zeus, headquartered in Orangeburg, South Carolina, employs over 2,400 people worldwide with facilities in Aiken, Columbia, Gaston, and Orangeburg, South Carolina; Branchburg, New Jersey; Chattanooga, Tennessee; San Jose, California; Arden Hills, Minnesota; and Letterkenny, Ireland.